Innate Pharma News and Activities
Presence
Innate Pharma develops immunotherapy medicines for cancer. Its products and services include antibody-based treatments and clinical development programs for healthcare providers, research partners, and patients.
Innate Pharma products and services overview:
- Cancer immunotherapy
- Antibody therapies
- Drug development
- Clinical research
Revenue: ~$25 million
Employees: 180
Headquarters: Marseille, France
Innate Pharma is one of the...
Innate Pharma is a company listed under the stock ticker IPH (FR).
Executives
View the org chart displaying its 24 main executives
Most searched biographies at Innate Pharma
- Jonathan Dickinson, Chief Executive Officer and Chairman of the Bo...
- Irina Staatz-Granzer, Chairman of the Board
- Gilles Brisson, Member of the Supervisory Board
Create your alert
to follow the executive moves at Innate Pharma.
Pharmaceuticals
Innate Pharma has 1,913 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).
Popular M&A news in Pharmaceuticals
- Eli Lilly has acquired Centessa Pharmaceuticals (posted on June 24 2026).
- Polpharma has acquired Biofarm (posted on June 24 2026).
- AbbVie has announced the acquisition of Apogee Therapeutics (posted on June 23 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Innate Pharma
- Outcome of Innate Pharma’s 2026 Annual General Meeting | Innate Pharma
- Innate Pharma to participate in the Jefferies Global Healthcare Conference | Innate Pharma
- Innate Pharma Reports First Quarter 2026 Business Update and Financial Results | Innate Pharma
- Number of shares and voting rights of Innate Pharma as of April 16, 2026 | Innate Pharma
- All press releases | Innate Pharma
- Innate Pharma announces conference call and webcast for Q1 2026 Business Update | Innate Pharma
- Innate Pharma to participate in the D. Boral Capital Global Conference | Innate Pharma
- Innate Pharma to hold its annual general meeting of shareholders on May 21, 2026 | Innate Pharma
- Innate Pharma to present MATISSE Phase 2 interim results of IPH5201 in Clinical Trials Plenary Session at AACR 2026 | Innate Pharma
- Number of shares and voting rights of Innate Pharma as of April 9, 2026 | Innate Pharma
- View more press releases Close
Social media about Innate Pharma
- Innate Pharma on Wikipedia, Google News & Yahoo Finance
- Innate Pharma on LinkedIn, X (Twitter) & YouTube
